In this context, a prospective phase II clinical trial (NCT03896854) investigated the safety and therapeutic efficacy of CD19-directed CAR-T cells in a cohort of 10 patients with relapsed CD19-positive t (8,21) AML. This evidence concerns the gene CD19 and acute myeloid leukemia.